Entera Bio to Engage at Key Healthcare Event
Entera Bio Ltd. (Nasdaq: ENTX), a pioneering company in the development of oral peptide and protein replacement therapies, is set to make a significant appearance at a prominent healthcare conference. The Company’s Chief Executive Officer, Miranda Toledano, will take part in an insightful fireside chat at the 8th Annual Evercore ISI Healthcare Conference. This event is a vital opportunity for Entera Bio to showcase its advancements and future directions.
Details of the Healthcare Conference
The discussion is scheduled for December 3, taking place from 9:10 to 9:30 AM. This engaging session will occur in Sevilla A, part of the in-person event running from December 3 to 5. Attendees will gain insightful information regarding Entera's latest progress and its innovative approaches to unmet medical needs.
Webcast Availability
A live webcast of the fireside chat will be made available for those unable to attend in person. Following the event, a replay will be accessible for 90 days, ensuring that interested parties can catch up on what promises to be a captivating discussion.
About Entera Bio
As a clinical stage company, Entera Bio focuses on transforming the treatment landscape for patients with significant unmet medical needs through oral peptide and protein therapies. The firm’s proprietary N-Tab™ platform empowers its pipeline that includes novel oral peptide formulations targeting various conditions. One of the standout candidates in Entera's arsenal is EB613, an oral therapy designed for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis. This innovative treatment has successfully met both primary and secondary endpoints in clinical trials, marking a significant step forward.
Innovative Pipeline Solutions
In addition to EB613, Entera Bio is advancing its EB612 program aimed at hypoparathyroidism, designed to be the first oral peptide replacement therapy of its kind. Furthermore, the company is poised to launch a groundbreaking oral oxyntomodulin for obesity treatment and a pioneering oral GLP-2 peptide for patients facing malabsorption issues like short bowel syndrome. Collaborations, especially with OPKO Health, amplify Entera's capacity to deliver these groundbreaking treatments.
Company Commitment and Innovation
Entera Bio is dedicated to changing the standard of care for challenging health issues, leveraging its cutting-edge technology to make rapid strides in the industry. Each product in its pipeline has the potential to revolutionize treatment protocols and improve patients' quality of life. The company is acutely aware of the challenges ahead but remains optimistic about its trajectory within the healthcare landscape.
Engagement and Communication
For those looking to explore more about Entera Bio's mission and offerings, the company provides comprehensive information on its website. Engaging through their channels, including LinkedIn, Twitter, and Facebook, offers insights into ongoing developments and news.
Frequently Asked Questions
What is Entera Bio known for?
Entera Bio is recognized for its innovative oral peptide and protein replacement therapies, targeting significant unmet medical needs.
Who is participating in the upcoming conference?
CEO Miranda Toledano will be participating in the fireside chat at the Evercore ISI Healthcare Conference.
When is the conference scheduled?
The conference will be held from December 3 to 5, with Entera's session on December 3 from 9:10 to 9:30 AM.
How can I watch the event if I can't attend?
A live webcast will be available, with a replay accessible for 90 days post-event.
Where can I find more information about Entera Bio?
You can visit their official website or follow them on social media platforms for the latest updates and information.
